Ann: Excellent initial Overall Survival Benefit in 1st line NSCLC, page-11

It's so funny that earlier this morning, Petra Capital updated a analyst report which is purely based on the FDA support and they put a price target of A$1.2 there. The report was pulled off on the website 5mins later. They must have found out 'oh hell', the real life data bump in and that A$1.2 target might not be current anymore.

A liitle while ago, CLSA updated a report with a price target of A$0.24. That is gotto be a serious typo! Almost few mins later they updated it with the 0.24 removed.

They OS data announced today is just one small piece within the survival data of TACTI002 part A. We have a lot more and more mature data to come. Even with just one single piece of readout, 25 months of mOS in TPS (PDL1)>1% population, no chemo, no double blockage toxicity (best of the best so far, if you compare with Checkmate 227, Keynote 598, .......... and many more), this is good enough to shake the whole clinical oncology field.

Yet this is only having a gentle kick on our share price. MSD, BMS, and the other top10, write THE letter to Immutep now.